Screening and chemoprevention of CRC Yaron Niv, M.D. Rabin Medical Center Tel-Aviv University.

Slides:



Advertisements
Similar presentations
CT COLONOGRAPHY. CRC TRENDS  Incidence decreased by 7%  Mortality decreased by 20%  Five year survival rates increased by 12%
Advertisements

Colon and Rectal Cancer Update
Individual Health vs. Public Health If you’re the 1/1000, it’s a 100% for you What absolute level of risk will society/an individual tolerate? Population-based.
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Update on Screening of Gastrointestinal Diseases Niraj Jani, M.D. Greater Baltimore Medical Center 1/30/15.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM April 3, 2014 Vol 3 Imperiale, T.F. et al Presented by Melissa Spera, MD.
Colorectal Cancer Ramon Garza III, M.D.. Colorectal CA DNA Sequencing Mismatch Repair Genes Genomics Role of PCR and FISH in Colon CA.
CCE 4: Bridging Clinical Expertise Using Predictive Computational Cancer Models CRC screening and follow-up – Semi-mechanistic model of CRC development.
DR Jameel Tariq Miro.  Lifetime incidence 5%  90% of cases occur after age 50  One-third of patients with colorectal cancer die from the disease 
Colorectal Cancer Screening & Surveillance: Anything New? Timothy C. Hoops, M.D.
Colorectal cancer: How do we approach health disparities? Marta L. Davila, MD, FASGE University of Texas MD Anderson Cancer Center.

 2 nd overall leading cause of cancer death in the United States › 3 rd in each sex  Approximately 6% of individuals in the US will develop a cancer.
Colon-Rectal Cancer Keith Bradley, MD National Alliance of Research Associates Programs NARAP.
Colorectal Cancer Screening John Pelzel MD Sleepy Eye Medical Center.
Joint Hospital Surgical Grand Round 19 June 2004.
Haley Hyde Jessica Fordham Jena Hamm  Colorectal cancer is a leading cause of cancer related deaths every year.  150,000 Americans will be diagnosed.
Clinical Practice Screening for Colorectal Cancer David A. Lieberman, M.D. N Engl J Med Volume 361(12): September 17, 2009.
Update on Colon Cancer Screening and Prevention
A Call to Action: Prevention and Early Detection of Colorectal Cancer (CRC)
Tryggvi Björn Stefánsson Dept of Surgery Landspitali University Hospital.
Screening for Colorectal Cancer Bruce D. Greenwald, MD Associate Professor of Medicine University of Maryland School of Medicine and Greenebaum Cancer.
Sharp L, Tilson L, Whyte S, Ó Céilleachair A
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Benchmarking For Colonoscopy
D. M. Kruss MD Kill the Cancer Do Screening now! Daniel M. Kruss, M.D. Kill the Cancer Do Screening now! Daniel M. Kruss, M.D.
AIMGP Seminar Series January 2004 Joo-Meng Soh Edited by Gloria Rambaldini CANCER SCREENING PART II.
Breast and Colorectal Cancer Screening in Family Care Clinic and their Outcomes Presented by Liana Poghosyan, MD Ne Moe, MD May 19, 2008.
COLORECTAL CANCER STATISTICS RISK ASSESSMENT SCREENING OPTIONS Luke Crantock.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
Andreas Adler Charité Medical University of Berlin, Virchow Clinic Campus Central Interdisciplinary Endoscopy Unit Narrow Band versus Conventional Endoscopic.
Colonoscopy; Surveillance Indications
COLORECTAL CANCER SCREENING in December of 2002 Jeffrey W. Frank, MD.
© Copyright Annals of Internal Medicine, 2014 Ann Int Med. 160 (5): ITC5-1. * For Best Viewing: Open in Slide Show Mode Click on icon or From the View.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
COMPARING YIELD AND COST OF FOBT AND FS IN AN AVERAGE RISK POPULATION: RESULTS AFTER 2 SCREENING ROUNDS N.Segnan MD, Ms Epi Center for Cancer Prevention.
Population Screening for Colorectal Cancer - update of evidences
1 Colorectal Cancer # 2 Cancer Killer # 2 Cancer Killer SCREENING SAVES LIVES.
An Evidence Based Approach to Colorectal Cancer Screening J. C. Ryan, M.D. Associate Professor of Medicine UCSF and SF VAMC 9/22/2014.
Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based fecal occult blood testing: a population-based controlled trial.
Barium Enema in the detection of Colon Cancer
1 Colorectal Cancer # 2 Cancer Killer # 2 Cancer Killer SCREENING SAVES LIVES.
Better Health. No Hassles. Colorectal Cancer Facts – The 2 nd leading cause cancer-related deaths in the Nation – Highly preventable – Caused 49,920 deaths.
Colon polyps Peter Stanich, MD
Brian Cox Research Associate Professor: Cancer epidemiology and screening University of Otago Hugh Adam Cancer Epidemiology Unit Department of Preventive.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Screening for Colorectal Cancer (CRC) Nov, 2007 A Aljebreen, FRCPC Division of Gastroenterology KKUH, Riyadh.
Colon Cancer Screening- Rationale Behind the Guidelines.
Modeling Efforts to Inform Countries’ Screening Decisions Ann Graham Zauber, Iris Vogelaar, Marjolein van Ballegooijen, Deb Schrag, Rob Boer, Dik Habbema,
Colon Cancer Matt Anderson, MD MSc Friday Teaching Seminar September 24, 2004.
Colorectal Cancer Screening Colorectal Cancer Screening VT SGNA Conference VT SGNA Conference October 24, 2015 October 24, 2015 Lynn Butterly, MD Lynn.
Colorado Colorectal Screening Program Holly Wolf University of Colorado School of Medicine
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
Colorectal Cancer Sunil T. Joseph, M.D..  Third leading cause of cancer-related death in U.S. (lung)  112,340 estimated new cases in 2007; 52,000 deaths.
Colorectal Cancer Screening – 2016 Update Howard Zhang, MD Chief of Gastroenterology and Hepatology Summa Health System.
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society.
Quality of Colonoscopy Using an endoscopic database to measure and improve quality AAPCE Memphis- November 5, 2011 David Lieberman MD Chief, Division of.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Hereditary Colorectal Cancer:
GASTROINTESTINAL ENDOSCOPY Volume 78, No. 3 : 2013 F1 김태영
Colonoscopic Polypectomy and Long-Term Prevention of Colorectal- Cancer Deaths N ENG J MED ;8 : Ann G. Zauber, Ph.D, Sidney J. Winawer,
USPSTF Colorectal Cancer Screening Guidelines: What’s New?
Colorectal Cancer Screening Guidelines
27th Annual Winter CME Conference
Colorectal Cancer (CRC)
Repeat Colonoscopy Recommendations
Module 4: Colorectal Cancer
Presentation transcript:

Screening and chemoprevention of CRC Yaron Niv, M.D. Rabin Medical Center Tel-Aviv University

Primary Vs. Secondary Prevention

Colorectal Cancer Screening Guide-lines For those at average risk (choosing from the following): l Annual FOBT l A sigmoidoscopy every 5 years l A combination of FOBT and sigmoidoscopy l A colonoscopy every 10 years or once in a life-time For those at increased risk: a colonoscopy

FOBT

Published FOBT Prospective, Randomized, Controlled Studies Series Minnesota Funen Nottingham Gothenburg Biennial Annual Biennial Biennial 2 screens Period 13 y 13 y 10 y 8 y 8y Colono 28% 38% 4% 4% 7% Mortality reduction 21% 33% 18% 15% 12%

Screening for CRC - FOBT Israel Average Risk Population Series A n C(%) P(%) NL Slater 85 mail, FP % Bat 86 FP % Rozen 87 volunteers % 92 volunteers % Eliakim 88 mail % Krieger 92 FP % Niv 92 FP % Total % A=approach C=compliance P=positive NL=neoplastic lesion

Survival Curve Screening of Colorectal Cancer Percentage of the Population

Sigmoidoscopy

Screening Sigmoidoscopy Reduced Rectal Cancer Mortality Direct evidence from 3 case control studies: l Selby, NEJM 1992;326: % l Newcomb, JNCI 1992;84: % l Muller, Arch Intern Med 1995;155: % 10 years protection

Screening FS in Israel (decrease in incidence , 16 to 10/100000) Neoplastic lesion Compliance (%) nyearSeries 28 (4.7%) Kiriat Uno (Bat) 45 (3.8%) Tel Aviv (Rozen) 42 (7.9%) Beer Sheva (Niv) 24 (5.7%) Dimona (Niv & Fraser) 8 (1.8%) Shouval & Nirim (Fraser & Niv) 8 (4.0%) Hagoshrim (Niv) 4 (4.0%) Chazor (Ilani, Pade & Niv) 16(13.5%) Beilinson (Niv) 175 (4.9%) Total

Screening for CRC - Comparison of FS and FOBT, Israel , Average Risk Population (FOBT 7,FS 5 papers) Method N Compliance Adenoma CRC % n % n % FOBT < Sigmo Total S/F 1/10 x 10 x 4

Colonoscopy

Screening Colonoscopy in the Average Risk Population l Visualization of the entire colon, biopsy and removal of all polyps l Proximal distribution of colonic neoplasm l Positive FOBT or sigmoidoscopy lead to total colonoscopy l FOBT alone may prevent fewer cancer deaths than colonoscopy l Effectiveness: 80% compliance by FOBT = 50% to colonoscopy l Once in a lifetime colonoscopy may be preferred (cost < $750)

National polyp study l A cohort of >1400 patients who had undergone colonoscopy and removal of adenomas was followed by colonoscopy for a mean of 5.9 years. l 70%-90% reduction was found in the incidence of colorectal cancers relative to what was expected based on 3 different historical control groups. Winawer, N Engl J Med 1993;329:1977

Preventive Effect of Colonoscopy 5-year incidence of adenomas after negative colonoscopy in asymptomatic average- risk persons 154 repeated colonoscopies (median 66m), 41 (27%) patients with adenoma, only one > 1 cm, no cancer! Rex, Gastroenterology 1996; 111:

Screening Colonoscopy in the Average Risk Population l Visualization of the entire colon, removal of all polyps l Rising proximal distribution of colonic neoplasm l Positive FOBT or sigmoidoscopy lead to total colonoscopy l FOBT alone may prevent fewer cancer deaths than colonoscopy l Effectiveness: 80% compliance by FOBT = 50% to colonoscopy l Once in a lifetime colonoscopy may be preferred (cost < $750) 50% 70%

Screening CRC - Distribution McCallion, Distribution of CRC in Northern Ireland: A 10% proximal shift, and 10% decrease in FS diagnostic yield ( ) FS 72% 62%

A distal significant polyp may predict a proximal lesion Advanced Proximal Neoplasm (APN) (size, histology, no.) Source distal APN l NEJM 92, GE 94 TA<1cm 0.8% TA>1cm 11.8% l NEJM 97 TA<1cm 16.0% TA>1cm 29.0% l Ann Int Med 98 TA<1cm 5.4% TA>1cm 7.9% l JAMA 99 Tubular 4.8% Villous 11.7%

Factors associated with an increased risk of APN Levin, JAMA 1999;281:1611 Lieberman, N Engl J Med 2000;343:162 Imperiale, N Engl J Med 2000;343:169 l Age > 65 years l Villous histology in distal adenoma l Distal adenoma > 1cm l Multiple distal adenomas l Positive family history of CRC

Screening Colonoscopy in the Average Risk Population l Visualization of the entire colon, removal of all polyps l Proximal distribution of colonic neoplasm l Positive FOBT or sigmoidoscopy lead to total colonoscopy l FOBT alone may prevent fewer cancer deaths than colonoscopy l Effectiveness: 80% compliance by FOBT = 50% to colonoscopy l Once in a lifetime colonoscopy may be preferred (cost < $750)

Published FOBT Prospective, Randomized, Controlled Studies Series Minnesota Funen Nottingham Gothenburg Biennial Annual Biennial Biennial 2 screens Period 13 y 13 y 10 y 8 y 8y Colono 28% 38% 4% 4% 7% Mortality reduction 21% 33% 18% 15% 12%

Screening Colonoscopy in the Average Risk Population l Visualization of the entire colon, removal of all polyps l Proximal distribution of colonic neoplasms l Positive FOBT or sigmoidoscopy lead to total colonoscopy l FOBT alone may prevent fewer cancer deaths than colonoscopy l Effectiveness: 80% compliance by FOBT = 50% to colonoscopy l Once in a lifetime colonoscopy may be preferred (cost < $750)

Positivity Rates of FOBT (%) St John, DDW, 1998; Rozen, Dig Dis Sci 1997.

FOBT - The Importance of Proper Evaluation Niv Y, JCG 1990;12:393 Kibbutz A Kibbutz B P l Population l > 40 y l FOBT + 33(25%) 8( 6%) <0.01 l Adenomas>1cm 2( 6%) 2(25%) <0.05

Simulation Model - Winawer Population of 100, CRC cases, 2391 deaths expected Cases Deaths Complication reduction reduction deaths Annual FOBT 2378(48%) 1330(56%) 52 Colonoscopy every 10 y 3570(72%) 1763(74%)

Screening Colonoscopy in the Average Risk Population l Visualization of the entire colon, removal of all polyps l Proximal distribution of colonic neoplasms l Positive FOBT or sigmoidoscopy lead to total colonoscopy l FOBT alone may prevent fewer cancer deaths than colonoscopy l Compliance has a direct effect on detection rate l Once in a lifetime colonoscopy may be preferred (cost < $750)

Compliance is the single most important determinant of effectiveness Lieberman, Gastroenterology 1995;109:1781. For the same decrease in mortality: FOBT 80% = = FOBT + FlEX. SIG. 60% = = COLONOSCOPY 50%

Screening Colonoscopy in the Average Risk Population l Visualization of the entire colon, removal of all polyps l Proximal distribution of colonic neoplasms l Positive FOBT or sigmoidoscopy lead to total colonoscopy l FOBT alone may prevent fewer cancer deaths than colonoscopy l Compliance has a direct effect on detection rate l Once in a lifetime colonoscopy may be preferred (cost < $750)

Cost-effectiveness Model for Colon Cancer Screening – Markov model – Amnon Sonnenberg (Sheba 2002) ($ per year of life saved) FOBT every year, Sigmo every 5 years, Colono once in a lifetime

Inappropriate CRC screening Fisher, AJGE 2005;100:2526 (North Carolina) l 500 consecutive primary care patients for whom FOBT had been ordered l 35% - inappropriate (at least one reason) l 18% - severe co morbid illness 13% - GI bleeding 7% - history of CRC or IBD 5% - had undergone colonoscopy within prior 5 years 3% - younger than 50 yr

Primary prevention l תזונה דלת שומן ועשירה בפירות, ירקות וסיבים l משקל תקין l המנעות מעישון ואלכוהול l תוספת סידן 1500 מג ' ליום l עדויות בלתי ישירות : אספירין, NSAIDs, סלניום, חומצה פולית, ויטמין D

Proliferation, Differentiation, Apoptosis l High fat diet – soluble fatty acids, bile acids – colonic epithelium cell damage – proliferation l Calcium precipitate fatty and bile acids l Calcium decreases cell proliferation and induces differentiation

Chemoprevention – prevention studies l Intermediate biomarkers – 1. Early – change in proliferation – number of crypt-proliferating cells and an upward shift of the proliferative zone 2. Late - recurrence of adenomatous polyps after polypectomy

Effect of a diet high in diary foods upon proliferation (early marker) Holt, JAMA 1998;280:1074 l 70 post polypectomy patients l Group A – diet containing 1200mg Ca/day, Group B – baseline diet Rectal biopsy – 0,6,12 months – [ 3 H]thymidine incorporation into DNA, differentiation markers l Significant lower proliferation, higher differentiation

Effect of calcium supplements on recurrence of adenomas (late marker) Baron, Ann NY Acad Sci 1999;889:138 l 930 post-polypectomy patients l Group A – 1200mg Ca/day, Group B – placebo l Colonoscopy – 1y, 2y l 19% decrease in recurrent adenoma, 24% decrease in the average number